Aligos Therapeutics, Inc. (ALGS) is experiencing a notable increase in its stock price today, likely influenced by recent developments related to Livmarli®, a treatment for Alagille Syndrome (ALGS). On December 18, 2024, CANbridge Pharmaceuticals announced that the Taiwan Food and Drug Administration has expanded the label for Livmarli to include patients as young as two months old. This expansion could potentially increase the market reach and adoption of Livmarli, which is significant for Aligos Therapeutics, given the drug's role in treating cholestatic pruritus associated with ALGS.
The current price of Aligos Therapeutics' stock is $36.89, reflecting a 7.02% increase from the previous close of $34.47. The stock opened at $35.51 and has traded between $34.62 and $37.00 so far today. With a trading volume of 214,638 shares, representing 62.05% of its average daily volume of 345,923, the stock is seeing moderate activity this morning.